Streetbeat News

CMND

Clearmind Medicine Inc.

https://www.clearmindmedicine.com

Industry

Biotechnology

Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Open

1.33

Mkt cap

5.4M

Volume

23K

High

1.34

P/E Ratio

-1.07

52-wk high

6.80

Low

1.32

Div yield

N/A

52-wk low

0.92

Aehr Test Systems shares surged 14% in pre-market trading after reporting better-than-expected Q1 earnings and revenue. Several other stocks, including NewGenIvf Group and ZenaTech, also saw significant pre-market movements.

Portfolio Pulse from Avi Kapoor

October 11, 2024 | 10:20 am

Clearmind Medicine's shares rise following Institutional Review Board approval for a Phase I/IIa clinical trial in the U.S. targeting alcohol use disorder.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:15 pm

Clearmind Medicine has received Institutional Review Board approval for its FDA clinical trial of CMND-100 at a second clinical site, focusing on treating alcohol use disorder.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:12 pm

Clearmind Medicine Inc. has filed an international patent for a combination therapy involving Ibogaine and N-Acylethanolamines, developed in collaboration with SciSparc Ltd. This therapy aims to improve the safety and efficacy of Ibogaine-based treatments for substance use disorders. The patent represents a significant advancement in mental health and addiction treatment.

Portfolio Pulse from Juan Spínelli

September 17, 2024 | 4:31 pm

Clearmind Medicine has announced the publication of a patent application under the Patent Cooperation Treaty for its ibogaine combination therapy. This development could enhance the company's intellectual property portfolio and potentially lead to new treatment options.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 8:08 pm

Clearmind Medicine and Yissum have filed an international patent application for new psychedelic compounds aimed at treating PTSD, addressing significant unmet medical needs.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 12:21 pm

Clearmind Medicine has announced the publication of a patent application under the PCT for a ketamine-based combination treatment. This development could enhance their intellectual property portfolio and potentially lead to new treatment options.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2024 | 8:28 pm

Clearmind Medicine Inc. (NASDAQ:CMND) has been granted a new U.S. patent for a compound aimed at regulating binge drinking. This patent is a significant milestone in their MEAI-based program, which targets Alcohol Use Disorder. Clearmind's patent portfolio now includes 29 patents across major markets.

Portfolio Pulse from Juan Spínelli

August 23, 2024 | 5:17 pm

Clearmind Medicine's shares rose following the announcement of a patent approval from the US Patent and Trademark Office.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2024 | 5:05 pm

Clearmind Medicine's shares rose following the approval of a new patent by the U.S. Patent and Trademark Office for its binge behavior regulator program.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 8:16 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.